Sionna Therapeutics Q1 2026 Earnings Results & Report

Sionna Therapeutics EPS Results

• Actual EPS: -$0.60
• Consensus EPS: -$0.52
• Beat/Miss: Missed by -$0.08
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 7 quarters

Sionna Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sionna Therapeutics (NASDAQ:SION) (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company is developing small-molecule therapies intended to address the underlying cause of CF by improving the production, processing, stability and function of defective CFTR proteins.

Sionna’s research platform is centered on CFTR modulators, including compounds designed to stabilize the CFTR protein’s nucleotide-binding domain 1 (NBD1). Its pipeline has included SION-638, an investigational NBD1 stabilizer intended for use as part of combination treatment regimens. The company’s approach is designed to potentially benefit people with a broad range of CFTR mutations, including patients who may not be adequately served by existing therapies.

Sionna conducts drug discovery and clinical development activities for the CF community. As a development-stage company, its investigational products remain subject to clinical testing and regulatory review, and there is no assurance that they will receive approval or become commercially available.